Type 2 myocardial infarction resulted from the left thoracic stomach

Abstract The universal definition of myocardial infarction (MI) provides five subtypes of acute myocardial infarction (AMI). We present an interesting case of a type 2 myocardial infarction caused by the dilation of the left thoracic stomach.

Neumomediastino y necrosis cutánea en asociación a dermatomiositis: presentación de un caso clínico y revisión de la literatura / Pneumomediastinum and cutaneous necrosis in dermatomyositis: Report of one case

We report a 37 years old male with a dermatomyositis treated with oral cyclophosphamide. He was admitted to the hospital due to a zone of skin necrosis with purulent exudate, located in the second left toe. A complete blood count showed a leukocyte count of 2,600 cells/mm³. A Chest CAT scan showed a pneumomediastinum with emphysema of adjacent soft tissue. Cyclophosphamide was discontinued and leukocyte count improved. The affected toe was amputated and a chest CAT scan showed a partial resolution of the pneumomediastinum. We discuss and review the pathogenesis, clinical presentation and management of pneumomediastinum and cutaneous necrosis in association with dermatomyositis.

A Phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: Results of an Indian population subanalysis.

Context: Currently, there is limited data on the prevention of chemotherapy-induced nausea and vomiting (CINV) in Indian patients. Aims: This post hoc study assessed the efficacy and safety of fosaprepitant compared with aprepitant for prevention of CINV in the Indian population. A subgroup analysis was performed from data collected in a phase 3 study of intravenous (IV) fosaprepitant or oral aprepitant, plus the 5-HT 3 antagonist ondansetron and the corticosteroid dexamethasone, in cisplatin-naοve patients with solid malignancies. Materials and Methods: Patients scheduled to receive cisplatin (≥70 mg/m 2 ) were administered a single IV dose of fosaprepitant dimeglumine (150 mg) on day 1 or a 3-day dosing regimen of oral aprepitant (day 1:125 mg, days 2 and 3:80 mg) with standard doses of ondansetron and dexamethasone. Patients recorded nausea and/or vomiting episodes and their use of rescue medication and were monitored for adverse events (AEs) and tolerability. Statistical Analysis Used: Differences in response rates between fosaprepitant and aprepitant were calculated using the Miettinen and Nurminen method. Results: In the Indian subpopulation (n = 372), efficacy was similar for patients in both the fosaprepitant or aprepitant groups; complete response in the overall, acute, and delayed phases and no vomiting in all phases were approximately 4 percentage points higher in the fosaprepitant group compared with the aprepitant group. Fosaprepitant was generally well-tolerated; common AEs were similar to oral aprepitant. Conclusions: IV fosaprepitant is as safe and effective as oral aprepitant in the Indian subpopulation and offers an alternative to the oral formulation.

The use of the Er:YAG 2940nm laser associated with amorolfine lacquer in the treatment of onychomycosis / Uso do laser de Er:YAG 2940nm associado ao esmalte de amorolfina no tratamento da onicomicose

Onychomycosis is a common disease, accounting for up to 50% of all ungual pathologies. We have been developing a clinical trial (ClinicalTrials.gov: NCT01528813) using a 2940nm Er:YAG laser to fractionally ablate human nails in vivo, aiming to increase topical amorolfine lacquer delivery to the nail unit, increasing the efficacy of topical treatment of distal and lateral subungual onychomycosis. Partial results have shown an increase in areas of nail plate free of disease. We believe that ablative lasers can increase the efficacy of topical onychomycosis treatment.

A onicomicose é afecção frequente, representando até 50% do total das doenças ungueais. Um ensaio clinico (ClinicalTrials.gov: NCT01528813) em atual desenvolvimento usa o laser de Er:YAG 2940nm para realizar ablação fracionada in vivo de unhas humanas visando aumentar a permeabilidade ungueal ao esmalte de amorolfina, visando aumentar a eficácia do tratamento tópico da onicomicose subungueal distal lateral. Resultados parciais tem demonstrado um aumento na área ungueal livre de doença nas unhas tratadas com o laser, em comparação ao uso isolado do esmalte. Acreditamos que lasers ablativos possam aumentar a eficácia do tratamento tópico da onicomicose.

Utilidad del suplemento de probioticos (Lactobacillus acidophilus y bulgaricus) en el tratamiento del Síndrome de Intestino Irritable / Probiotic supplement (Lactobacillus acidophilus and bulgaricus) utility in the treatment of irritable bowel syndrome

El Sindrome de Intestino Irritable (SII), es un transtorno funcional muy común y causa frecuente de consulta en gastroenterología, su fisiopatología es multifactorial y se caracteriza por dolor abdominal, distensión y alteración de los hábitos defecatorios, su terapia es básicamente sintomática (loperamida, antiespasmódicos, antidepresivos,etc).Recientemente se ha incorporado al tratamiento, el uso de probióticos que podrían mejorar su sintomatología. POBLACIÓN Y MÉTODO: Ensayo Clínico doble ciego aleatorizado simple, multicentrico que incluyó pacientes con diagnóstico de SII basado en criterios de Roma III. A estos se les administró Bromuro de Pinaverio mas placebo o Bromuro de Pinaverio mas Probiótico. La intensidad de los síntomas y el efecto del tratamiento fue valorado de acuerdo a Score de Francis antes y al final del tratamiento. Los cálculos fueron hechos con el programa SPSS 12.0.IC 95% RESULTADO. Se evaluaron 51 pacientes con promedio de edad de 43 años, mayoritariamente mestizos, 75%(38) casados y 55%(28) del sexo femenino, se encontró diferencias significativas en 4 variables de comparación: Dolor abdominal, Severidad del dolor, Días de dolor, y el Score total al final del tratamiento. CONCLUSIONES Los Probióticos utilizados como suplemento son efectivos en mejorar la sintomatología del SII.

Background: Irritable bowel syndrome (IBS) is a very common functional condition and a frequent cause of consultation in gastroenterology. With a multifactorial pathophysiology IBS is characterized by abdominal pain, distension and altered bowel habits. Loperamide, antispasmodics and antidepressants are symptomatic relievers of this disorder. Recently probiotics were incorporated to therapy, and could improve the symptomatology. Methods: multicenter randomized placebo-controlled trial that included IBS patients, diagnosed with Rome III criteria. The patients were given pinaverium bromure and placebo or pinaverium bromure and probiotics for 3 weeks. The intensity of symptoms and the effect of therapy were evaluated with the Francis Score, before and after the treatment. Statistics were done with SPSS 12.0 (C.I 95%). Results: 51 patients were evaluated, with an average age of 43 years old, mostly mestizo, 75% (38) married and 55% (28) female. There were statistical differences in four variables: abdominal pain, intensity of pain, days of pain and total score at the end of therapy. Conclusions: Probiotics used as supplement are effective in improving symptomatology of IBS.

A Randomized, Open Label, Multicentre Study to Evaluate the Safety and Efficacy of Cough Mixture CS1 (Pholcodeine and Promethazine - Tixylix) Versus CS2 (Noscapine, Ammonium Chloride, Sodium Citrate) in Treatment of Children with Dry Cough.

The objective of this study was to compare the efficacy and safety of cough mixture containing pholcodeine and promethazine - Tixylix (CS1) to a cough mixture which has noscapine, ammonium chloride, and sodium citrate (CS2) as its constituents in treatment of children suffering from dry cough. A total of 208 patients were enrolled at 4 sites. Of these, 179 (94 receiving CS1 and 99 receiving CS2) completed the study. Results of this study suggest that both the cough mixtures were comparable as per evaluation of their primary parameters. According to global assessment for efficacy and tolerability by parents on Day 7, Group CS1 performed better than CS2. It was also observed that no AE was reported in Group CS1 as compared to 2 AEs in Group CS2. To conclude, cough mixture combination of pholcodeine and promethazine - Tixylix exhibited efficacy and safety that was comparable with cough mixture which has noscapine, ammonium chloride, and sodium citrate. It was proven to be efficacious, safe and well tolerated in the select population.

Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting.

The episodes of nausea and vomiting which follow each cycle of chemotherapy are the most troublesome side effect experienced by cancer patients. Introduction of ondansetron was a definite therapeutic advance in treating chemotherapy induced nausea and vomiting (CINV) with more effectiveness with corticosteroids. However, the protection remained largely limited to acute phase of CINV with little or no effect over delayed phase. Aprepitant, a drug that antagonizes the effect of substance P on neurokinin type 1 receptor showed promising results in controlling both phases of CINV. This drug is well absorbed orally with a t max of about four hours. The addition of aprepitant to ondansetron and dexamethasone was found to be superior to ondansetron and dexamethasone alone in clinical trials with patients taking high and moderate emetogenic chemotherapy. This drug also showed a good safety profile, but its inhibitory effect on CYP3A4 may result in clinically significant drug interactions needing dose modifications of co-administered drugs. The National Comprehensive Cancer Network guidelines for CINV recommends the use of aprepitant with high and moderately emetogenic anticancer drugs. Results of ongoing clinical trials with aprepitant and other agents of this new class of antiemetics are awaited and may alleviate the sufferings of cancer patients.

The Effect of Mosapride on Quality of Life in Functional Dyspepsia / 대한소화기학회지

BACKGROUND/AIMS: It is unknown whether the prokinetics improve the quality of life in patients with functional dyspepsia. Thus, we evaluate the effect of the mosapride, selective 5-HT4 agonist, on the symptom and life quality of patients with functional dyspepsia using the Nepean dyspepsia index-Korean version (NDI-K), a reliable and validated disease-specific quality of life questionnaire. METHODS: A single, open trial was performed in 129 patients with functional dyspepsia. Patients were received mosapride 5 mg t.i.d before each meal for 4 weeks. The symptoms and quality of life were measured with the NDI-K at baseline and 4 weeks. The responsiveness of the NDI-K was evaluated by correlation with symptom scores. RESULTS: All the 15 symptom scores and the dyspepsia score decreased after treatment (p<0.05). The total symptom score decreased from 60.9 +/- 25.8 to 24.7 +/- 20.4 (p=0.001). Correlations were observed between the total symptom score and the NDI-K score (r=0.47, p=0.001), and between the total symptom score and each score in 5 subscales (r=0.25-0.44, p=0.001). The NDI-K score was significantly increased in the effective group whose dyspepsia score decreased more than 50% of the score at baseline, compared with that of ineffective group. Any significant adverse effect and prolongation of QT interval were not occurred in all patients. CONCLUSIONS: A prokinetic drug, mosapride improves the symptoms and the quality of life in patients with functional dyspepsia.

Reboxetina no tratamento da bulimia nervosa / Reboxetine in the treatment of bulimia nervosa

É vasta a literatura demonstrando a eficácia dos antidepressivos inibidores seletivos da recaptação de serotonina na Bulimia Nervosa, diminuindo a freqüência do comportamento alimentar compulsivo e dos vômitos. A boa resposta terapêutica aos agentes farmacológicos noradrenérgicos, como a desipramina e a reboxetina, embora menos encontrada na literatura, também já foi documentada. O presente relato de caso descreve o tratamento de uma paciente com Bulimia Nervosa utilizando-se reboxetina na dose de 4 a 8 mg ao dia. A resposta terapêutica vem confirmar os resultados favoráveis do uso desta droga no tratamento da Bulimia Nervosa

Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome

Background: Growing evidence points to irritable bowel syndrome physiologically as a disease of the enteric nervous system characterised by hypermotility. The aim of this study was to investigate the action of pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract on basal and post-prandial recto-anal motility of 40 irritable bowel syndrome patients in a random, double blind and placebo controlled trial. Methods: Pinaverium bromide (50 mg) or placebo was taken orally t.i.d with food. Myoelectrical and mechanical activities of the rectum and the internal anal sphincter were recorded before treatment for 2 h in the fasting state and for an additional 2 h post-prandial. Results: Post-prandial rectal spike amplitude and frequency as well as the spontaneous recto-anal inhibitory reflex frequency decreased after pinaverium bromide (P < 0.01) but not after placebo. Conclusions: These results suggest that the calcium channel blockers acting selectively on the gastrointestinal tract may have a therapeutic role in patients with irritable bowel syndrome.

Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker: a randomized double-blind placebo; controlled trial

ANTECEDENTES: El síndrome de intestino irritable es una de las principales causas de días perdidos en el trabajo. Como no se conoce hasta ahora ningún tratamiento realmente efectivo, los pacientes acuden con muchos médicos probando todo tipo de medicinas, durante largos períodos de tiempo que duran años. Así, el síndrome de intestino irritable se ha convertido en un serio problema socio-económico que afecta a la familia y al trabajo. METODOS: Se efectuó un estudio aleatorio, doble ciego, controlado con placebo en 40 pacientes consecutivos con síndrome de intestino irritable (edad media: 31.4 +/- 1.8, rango 17-52 años; mujeres). Se administró oralmente bromuro de pinaverio (50 mg) o placebo, tres veces al día con las comidas. RESULTADOS: El bromuro de pinaverio disminuyó la duración del dolor de varias horas a pocos minutos (p<0.05) y mejoró los síntomas recto-anales. No hubieron efectos secundarios. CONCLUSIONES: El bromuro de pinaverio es inocuo y produce beneficio significativo en la calidad de vida del paciente, por lo que puede ser un medicamento valioso en el tratamiento de pacientes con síndrome de intestino irritable.